药物洗脱支架后联用西洛他唑可降低股腘动脉病变支架内再狭窄
本研究为ZEPHYR研究的事后分析,纳入399例症状性外周动脉疾病患者共475处股腘动脉病变,均接受紫杉醇洗脱支架且术后维持阿司匹林加噻吩吡啶治疗。
要点
- 股腘动脉药物洗脱支架术后加用西洛他唑,1年再狭窄率显著低于未用组。
- 匹配后西洛他唑组再狭窄率33%,未用组51%,比值比0.5。
- 研究人群合并糖尿病71%、透析31%、严重肢体缺血29%。
核心结论
- 倾向评分匹配分析显示,股腘动脉药物洗脱支架植入后加用西洛他唑与1年再狭窄发生率显著降低相关。
研究设计与样本
- 本研究为ZEPHYR研究的事后分析,ZEPHYR为前瞻性多中心研究,评估Zilver紫杉醇洗脱支架治疗股腘动脉病变。
- 分析纳入399例患者共459条肢体475处病变,均维持阿司匹林加噻吩吡啶治疗,伴或不伴西洛他唑,随访1年。
- 西洛他唑组93例,未用西洛他唑组382例,倾向评分匹配91对。
主要发现
- 比值比为0.5(95%CI 0.3-0.8)。
- 再狭窄评估采用双功超声(收缩期峰值流速比>2.4)或血管造影(直径狭窄≥50%)。
- 人群中糖尿病占71%,透析占31%,严重肢体缺血占29%,原发病变占76%,支架内再狭窄占15%。
关键数值与推荐
- 再狭窄定义:双功超声收缩期峰值流速比>2.4或血管造影直径狭窄≥50%。
- 比值比0.5(95%CI 0.3-0.8)。
临床怎么用
- 对于股腘动脉病变接受药物洗脱支架植入的症状性外周动脉疾病患者,在阿司匹林加噻吩吡啶基础上加用西洛他唑可能降低1年再狭窄风险。
- 需结合患者合并症(如糖尿病、透析、严重肢体缺血)个体化评估联用西洛他唑的获益与风险。
局限性
- 本研究为ZEPHYR研究的事后亚组分析,非随机对照设计。
- 西洛他唑组样本量较小(93例),倾向评分匹配后为91对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cilostazol improves clinical endovascular therapy outcomes for femoropopliteal (FP) lesions in patients with symptomatic peripheral arterial disease, but whether it also has clinical benefits for patients after drug-eluting stent implantation remains unclear. METHODS: This study is a subanalysis of the ZilvEr PTX for tHe Femoral ArterY and Proximal Popliteal ArteRy (ZEPHYR) study, a prospective multicenter study investigating FP lesions treated with the Zilver (Cook Medical, Bloomington, Ind) paclitaxel-eluting stent. The present study analyzed 475 lesions in 459 limbs of 399 patients who maintained therapy with aspirin and thienopyridine, with or without cilostazol, during the 1-year follow-up period. RESULTS: Restenosis rates at 1 year were assessed with duplex ultrasound imaging (peak systolic velocity ratio >2.4) or angiography (≥50% diameter stenosis) and compared in the groups with and without cilostazol. Propensity score matching was performed to minimize intergroup differences in baseline characteristics. The present study included 93 cilostazol-treated and 382 cilostazol-free cases. Among the patients, 71% had diabetes mellitus and 31% were on dialysis. Critical limb ischemia accounted for 29% of cases. The prevalence of de novo lesions was 76%, and in-stent restenosis was present in 15%. Propensity score matching was performed in 91 pairs. The 1-year restenosis rate was 33% (95% confidence interval [CI], 23%-43%) in the cilostazol-treated group and 51% (95% CI, 41%-62%) in the cilostazol-free group (P = .008). The odds ratio was 0.5 (95% CI, 0.3-0.8). CONCLUSIONS: The propensity score-matching analysis demonstrated that additional cilostazol administration was associated with a significantly lower restenosis incidence 1 year after drug-eluting stent implantation for FP lesions.
引用
- Zen K, Takahara M, Iida O, et al. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. J Vasc Surg. 2017. PMID: 28073668. doi:10.1016/j.jvs.2016.10.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。